Drug intelligence / Profile preview

VCL-2510

Development stage: Phase 1
Lead developer: Vical
Modality: DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Prophylactic Vaccines → Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

VCL-2510 is a plasmid DNA vaccine encoding the gene for the malaria circumsporozoite protein from *Plasmodium falciparum* (PfCSP). It is designed to induce immune responses against malaria by targeting the liver stages of the parasite. The vaccine is administered intramuscularly and has been tested for safety and immunogenicity in clinical trials.

Other names: PfCSP DNA vaccine

Targets

CSP (Circumsporozoite protein)

Beyond the preview

Go deeper on VCL-2510.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VCL-2510.

Explore the full profile